Sun Pharma Q4 Results: Net profit at ₹1,984 crore, revenue up 15%, dividend declared


Sun Pharmaceuticals announced its Q4FY23 results on May 26, reporting a consolidated net profit of 1,984 crore, compared to a net loss of 2,277 crore in the corresponding period last year. The pharma major’s revenue from operations during the January-March quarter came in at 10,930.6 crore, registering a growth of 15.7 per cent, compared to 9,446.8 crore in the year-ago period.

The company’s board recommended a final dividend of Rs. 4.00 per equity share of Re. l each, subject to the approval of shareholders. On the operating front, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) during the fourth quarter stood at 2,803 crore, reporting a rise of 19.7 per cent, compared to 2,340.4 crore in the same period last year.

The yearly rise in revenue was aided by double-digit growth in the specialty segment and robust sales in the domestic formulations business, along with some contribution from the sales of the generic Revlimid in the US market.

At 3:15 pm, shares of Sun Pharma were trading 3.02 per cent higher at 973.25 apiece on the BSE.


This copy is being updated

Know your inner investor
Do you have the nerves of steel or do you get insomniac over your investments? Let’s define your investment approach.

Take the test

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint.
Download The Mint News App to get Daily Market Updates.


Updated: 26 May 2023, 03:14 PM IST

Article Source:Money Control

Leave a Reply

Your email address will not be published. Required fields are marked *